Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker-guided individualized immunosuppression in living donor kidney transplant recipients
2017-002293-39Phase 4Active
- Sponsor
- Trackyourmed
- Start
- Aug 2017
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of tacrolimus, mycophenolate mofetil, basiliximab, methylprednisolone, prednisone and 1 more in kidney allograft rejection (2 arms), sponsored by Trackyourmed. Primary endpoint: Composite efficacy endpoint at 2 years. Started Aug 2017; status: active.
02
Drugs
tacrolimusmycophenolate mofetilbasiliximabmethylprednisoloneprednisone
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on 2017-002293-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002293-39.